In 2024 and as of 15 November 2024, Dengue cases were reported in the following countries:
Burkina Faso: a total of 89’728 dengue cases (91 deaths) have been reported in all 13 regions. Most cases (51%) have been reported from the Center region. DENV-1 and DENV-3 viruses have been identified.
Cabo Verde: a total of 35’230 dengue cases (14’137 confirmed; 21’093 suspected cases ) have been reported from all nine islands. Santiago Island accounted for 82% of all confirmed cases. Serotypes DENV-1 and DENV-3 were detected.
Senegal: a total of 181 confirmed dengue cases have been identified in nine regions in Senegal, with Pikine district in Dakar region having the most cases (16), 20% of all cases. Other regions reporting a high number of cases include Thies 16 (20.0%), Louga 7 (9.0%), Fatick 6 (7.0%), Kaffrine 6 (7.0%), and Saint-Louis 4 (5.0%).
Sudan: Dengue is currently emerging as a public health problem in most states of Sudan with more than 6’000 cases reported.
Prevention: Optimal mosquito bite protection 24/7, also in cities (also against other mosquito-borne diseases such as malaria, Zika, chikungunya).
In case of fever, apply paracetamol products and hydration. If you have a fever, avoid taking medications containing acetylsalicylic acid (e.g., Aspirin®), as this can increase the risk of bleeding during a dengue infection. However, do not stop taking medications containing acetylsalicylic acid if it is already part of your regular treatment for an underlying condition.
In case of fever, malaria should be always ruled out by blood tests.
Note on vaccination against dengue fever with Qdenga®:
The Swiss Expert Committee for Travel Medicine (ECTM) recommends a vaccination with Qdenga® only for travelers from 6 years old who have evidence of previous dengue infection and who will be exposed in a region with significant dengue transmission. For details, see ECTM Statement.